key: cord-0884882-hs69j3w9
authors: Baba, Ryuta; Oki, Kenji; Itcho, Kiyotaka; Kobuke, Kazuhiro; Nagano, Gaku; Ohno, Haruya; Yoneda, Masayasu; Hattori, Noboru
title: Angiotensin-converting enzyme 2 expression is not induced by the renin–angiotensin system in the lung
date: 2020-10-05
journal: ERJ Open Res
DOI: 10.1183/23120541.00402-2020
sha: c6eea396e1cbc3b29d18d76198ecd8dfc97d9b4a
doc_id: 884882
cord_uid: hs69j3w9

Pulmonary expression of angiotensin-converting enzyme 2, which is a receptor of severe acute respiratory syndrome coronavirus 2, is not regulated by angiotensin II or renin–angiotensin system inhibitors #COVID19 https://bit.ly/3fkopuO

Therefore, we aimed to investigate whether ACE2 expression is regulated by RAS activation or inactivation in pulmonary cells. First, we stimulated a human nonsmall cell lung cancer cell line (Calu-3 

A-II-stimulated cells were treated with ACE inhibitors including lisinopril and captopril and A-II receptor Type 1 blockers including losartan and valsartan, respectively. RNA extraction and quantitative PCR (qPCR) assays were performed as previously reported [6] ; qPCR primers used to target ACE2 were 5′-CGAAGCCGAAGACCTGTTCTA-3′ and 5′-GGGCAAGTGTGGACTGTTCC-3′. ACE2 expression levels were determined as arbitrary units normalised against GAPDH expression, which was measured as previously described [6] , and the results were expressed as fold change relative to unstimulated control cells (figure 1).

As shown in figure 1 , there was no alteration in ACE2 expression in Calu-3 and A549 cells under all conditions. To address ACE2 expression by A-II in other tissues, we investigated the effects of A-II on ACE2 expression in a human adrenocortical carcinoma (HAC15) cell line. A-II stimulation significantly increased ACE2 expression by 1.5-fold in the HAC15 cell line ( p<0.05, figure 1 ).

Our results showed that activation or inactivation of RAS did not influence ACE2 expression in pulmonary cells, and thus RAS inhibitors are unlikely to alter ACE2 expression in lung epithelium. Even in the acute phase of severe COVID-19, when RAS is activated because of catecholamine release and/or hypovolaemia, ACE2 expression might not be upregulated in pulmonary cells. ACE2 and angiotensin II receptor Type 1 (AGTR1) expression in the human lung is considerably lower than that in the human adrenal gland [7] . Our in vitro study suggests that pulmonary expression of ACE2 is not influenced by A-II or RAS inhibitors.

Angiotensin 1-7, which is generated from A-II by ACE2, shows anti-inflammatory effects [8] . In a meta-analysis of four studies, GAO et al. [9] indicated that RAS inhibitor use tends to have a low risk of @ERSpublications Pulmonary expression of angiotensin-converting enzyme 2, which is a receptor of severe acute respiratory syndrome coronavirus 2, is not regulated by angiotensin II or renin-angiotensin system inhibitors #COVID19 https://bit.ly/3fkopuO mortality in COVID-19. ACE2 upregulation induced by RAS inhibitors may increase the systemic circulation of angiotensin 1-7 and thus may lead to a protective effect against severe COVID-19.

The current study has several limitations. Since this study was performed only in vitro using cancer-derived cell lines, primary lung epithelial cells or airway epithelial cells incubated using an air-liquid interface would be more efficient in clarifying ACE2 expression [10] . Human lung epithelial cells might regulate ACE2 expression differently. Furthermore, chronic effects of A-II or RAS inhibitors were not examined in this study. Further studies are needed to investigate the association between RAS and pulmonary ACE2 expression in vivo and in normal lung epithelial cells. The functional mechanisms involved other than ACE2 expression, such as viral entry and replication, also need to be clarified in the development or exacerbation of COVID-19.

At this point in time, our findings support the recommendation of most medical societies not to withdraw RAS inhibitors to avoid COVID-19. Although we could not show conclusively that RAS inhibitors were not associated with the development or exacerbation of COVID-19, we believe that this study could inform future studies related to COVID-19. 1) supplemented with 10% Cosmic Calf serum until confluence. Cells were then incubated in serum-deprived medium with 0.1% serum for 24 h, after which the medium was replaced with fresh medium containing 0.1% serum with or without ARB or ACEi for 30 min. A-I or A-II were added to the medium, and cells were collected after 3 h of incubation for subsequent quantitative PCR assay. Statistical analyses were performed by one-way ANOVA; no significant differences were observed in A549 cells or Calu-3 cells ( p>0.05). The difference was analysed by t-test in HAC15 cells: A-II stimulation significantly increased ACE2 expression ( p<0.05). Results were expressed as fold change relative to unstimulated control cells. In each experiment, samples were assayed in triplicate. Three independent experiments were performed. Los: losartan; Val: valsartan; Lis: lisinopril; Cap: captopril.

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis

Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review

Angiotensin 1-7 suppresses angiotensin II mediated aldosterone production via JAK/STAT signaling inhibition

Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics

COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Expression of the SARS-CoV-2 ACE2 receptor in the human airway epithelium